Bayer

Germany’s Bayer won fast-track status from U.S. drugs regulators for a new blood thinner designed to prevent certain types of strokes, as the company seeks to follow up on the success of the anticoagulant Xarelto.

Bayer

Older adults taking Bayer AG’s blockbuster blood thinner pill Xarelto for a common type of irregular heart rhythm had significantly higher rates of serious bleeding and stroke compared to those taking rival pill Eliquis, a U.S. study showed.

Abbott’s Xience family of stents received U.S. Food and Drug Administration approval for one-month (as short as 28 days) dual anti-platelet therapy labeling for high bleeding risk patients in the United States.

Bristol Myers Squibb Co. reported lower-than-expected first-quarter profit on April 29 as sales of the company’s high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.

A judge in Hawaii ordered Bristol-Myers Squibb Co. and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from the blood thinner Plavix.

The likelihood that a coronavirus infection will prove fatal dropped by nearly a third since April due to improved treatment, researchers at the University of Washington’s Institute for Health Metrics and Evaluation (IHME) said.

The painkiller aspirin will be evaluated as a possible treatment for Covid-19 in one of Britain’s biggest trials, which will assess whether it might reduce the risk of blood clots in people with the disease.

Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.

The National Institutes of Health launched two of the three late-stage clinical trials to test the effectiveness and safety of different types of blood thinners in treating Covid-19 among adults.

A federal court upheld patent claims regarding Bristol Myers Squibb and Pfizer’s Eliquis, which blocks generic rivals from carving out a share of the market for at least six years.